Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 2 · below the Ichimoku cloud · RSI 50 · MACD above its signal
None of the 29 investors followed here reported a position in BIXT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BIXT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -43.8 | 5.6 | -0.2 | -26.0 | -4.2 | -18.2 | -8.7 | -12.4 | 14.9 | -6.3 | −70.4% | ||
| 2025 | 11.1 | -20.5 | 77.7 | 13.3 | -1.9 | -33.1 | -10.3 | -31.1 | 9.6 | -3.2 | 19.4 | -7.6 | −15.7% |
| 2024 | -15.1 | -13.6 | -3.8 | 5.0 | 5.3 | -17.6 | 24.3 | -28.6 | 28.7 | -18.2 | 2.8 | -2.8 | −40.1% |
| 2023 | 1.1 | -17.5 | 11.2 | 14.0 | -36.8 | -40.7 | -21.3 | 107.4 | -45.2 | -8.8 | -18.5 | 18.7 | −68.7% |
| 2022 | -37.5 | -59.9 | 72.5 | 131.2 | -50.0 | 60.0 | 31.2 | 147.6 | -33.4 | -42.3 | 5.0 | 14.3 | +20.0% |
| 2021 | -24.0 | -1.4 | -5.6 | 0.0 | -99.4 | -80.0 | 50.0 | 66.7 | 120.0 | 127.3 | 700.0 | 1900.0 | +66.7% |
| 2020 | -50.7 | 471.4 | -59.2 | -23.3 | -20.0 | -10.0 | -22.2 | 21.4 | -73.5 | 255.6 | 81.2 | -17.2 | −15.5% |
| 2019 | 2.0 | -48.8 | 31.6 | 185.7 | 26.0 | -32.5 | 52.9 | -26.9 | -26.3 | -14.3 | -5.0 | -50.2 | −44.3% |
| 2018 | -7.1 | -40.0 | 2.6 | -12.5 | -28.6 | 12.0 | 25.0 | -94.3 | 233.3 | 145.0 | 53.1 | -32.0 | −75.7% |
| 2017 | 50.6 | 75.6 | -54.3 | -4.8 | -34.5 | 50.4 | -18.3 | -28.6 | -8.7 | -2.9 | -16.7 | 723.5 | +302.3% |
| 2016 | -13.4 | -50.0 | 205.0 | -16.1 | 36.7 | -17.9 | 13.7 | -15.9 | -10.0 | 1.0 | -37.1 | -44.7 | −62.3% |
| 2015 | 0.0 | -37.5 | -60.0 | 190.0 | 3.4 | -66.7 | -10.0 | -1.1 | -5.0 | -14.7 | -2.9 | -34.0 | −88.5% |
| 2014 | -40.7 | 4.3 | 16.4 | -15.3 | -26.7 | -24.2 | -12.5 | -42.9 | 2.0 | -21.6 | -17.5 | 21.2 | −86.4% |
| 2013 | -55.6 | 105.0 | 0.0 | -26.8 | 36.7 | -26.8 | 16.7 | 4.3 | 256.2 | -15.4 | -37.3 | -14.5 | +31.1% |
| 2012 | -7.5 | 2.7 | -23.7 | 8.6 | -4.8 | 31.7 | -30.4 | 27.3 | -35.7 | -12.9 | -0.5 | 15.4 | −43.8% |
| 2011 | 120.0 | -20.5 | -22.9 | 100.0 | -44.4 | -20.0 | 37.5 | -4.5 | -33.3 | 35.7 | -13.7 | -2.4 | +20.0% |
| 2010 | 0.0 | -68.0 | 0.0 | 350.0 | 122.2 | -37.5 | 10.0 | -9.1 | -40.0 | -16.7 | -20.0 | −20.0% |
No insider transactions reported for BIXT.
No analyst coverage for this instrument.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.